Articles tagged “MEF2C Haploinsufficiency Syndrome”

Clinical Trials

New Brain-Penetrant CDK2 Inhibitor Begins Human Trials

On May 29, 2026, the first patient was dosed with AL-605, a new CDK2 inhibitor developed by Alaw Therapeutics, in a clinical trial. Here's why that's important for MEF2C...

2026-06-13

Foundation News

MEF2C Community Roundup: Fundraising, Registry Growth and Global Awareness

While scientific breakthroughs often capture the headlines, they rarely happen in isolation.

2026-06-13

Foundation News

From Sydney to New York: MEF2C Foundation Australia Leads the Global Charge

MEF2C Foundation Australia is at the frontline of the Volare Study, the first longitudinal natural history study for MCHS.

2026-06-09

Foundation News

Milestone Numbers: US MEF2C Foundation Registry Reaches 170 Patients

The US MEF2C Foundation has reached a critical data threshold, with 170 patients now registered in the foundation's registry. This growing longitudinal dataset is fueling the path toward human clinical trials for MEF2C Haploinsufficiency Syndrome.

2026-06-08

Historical

Naming the Unnameable: The Emergence of MEF2C Haploinsufficiency Syndrome

For countless families, the journey for their child struggling with unexplained developmental delays, epilepsy, or severe movement impairment often reached a critical point: moving from a world of frustration with "we don't know" to a moment of nascent hope with "now we have a name."

2026-06-01